Genelux Co. (NASDAQ:GNLX - Free Report) - Equities research analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Genelux in a research report issued to clients and investors on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.84) per share for the year, up from their previous forecast of ($0.88). HC Wainwright currently has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Genelux's current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux's Q4 2024 earnings at ($0.14) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.07) EPS and FY2028 earnings at $1.23 EPS.
Genelux Stock Down 5.5 %
NASDAQ GNLX traded down $0.17 during trading hours on Thursday, hitting $2.91. 91,366 shares of the company were exchanged, compared to its average volume of 205,462. The company has a 50 day moving average of $4.06 and a two-hundred day moving average of $3.10. The firm has a market cap of $100.51 million, a price-to-earnings ratio of -3.06 and a beta of -1.41. Genelux has a 52-week low of $1.60 and a 52-week high of $6.50.
Genelux (NASDAQ:GNLX - Get Free Report) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09).
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in GNLX. Marshall Wace LLP lifted its position in shares of Genelux by 51.4% during the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock worth $368,000 after purchasing an additional 52,958 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Genelux during the 4th quarter worth about $41,000. LPL Financial LLC increased its holdings in shares of Genelux by 72.3% in the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company's stock valued at $222,000 after acquiring an additional 39,516 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Genelux during the 4th quarter worth about $25,000. Finally, LifeSteps Financial Inc. lifted its stake in Genelux by 11.1% during the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company's stock worth $205,000 after purchasing an additional 8,715 shares during the last quarter. Institutional investors and hedge funds own 37.33% of the company's stock.
Genelux Company Profile
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Featured Articles
Before you consider Genelux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.
While Genelux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
